Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects

E. Spina, A. Avenoso, G. M. Campo, M. G. Scordo, A. P. Caputi, E. Perucca

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aims: The aim of the study was to characterize further the role of CYP3A4 in the metabolism of tricyclic antidepressants. Methods: The effect of oral ketoconazole (200 mg day-1 for 14 days) on the kinetics of a single oral dose of imipramine (100 mg) and desipramine (100 mg) was evaluated in two groups of six healthy male subjects. Results: Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 ± 0.21 to 0.96 ± 0.20 l h-1 kg-1, mean ± s.d.; P <0.02), a prolongation in imipramine half-life (from 16.7 ± 3.3 to 19.2 ± 5.4 h, P <0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 ± 1707 to 3180 ± 1505 nmol l-1 h, P <0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected. In the subjects given desipramine, no significant changes in desipramine and 2-hydroxy-desipramine kinetics were observed during ketoconazole treatment. Conclusions: These findings indicate that ketoconazole, a relatively specific inhibitor of CYP3A4, inhibits the N-demethylation of imipramine without affecting the 2-hydroxylation of imipramine and desipramine. This interaction, confirms that CYP3A4 plays a role in the demethylation of tricyclic antidepressants.

Original languageEnglish
Pages (from-to)315-318
Number of pages4
JournalBritish Journal of Clinical Pharmacology
Volume43
Issue number3
Publication statusPublished - 1997

Fingerprint

Desipramine
Ketoconazole
Imipramine
Healthy Volunteers
Pharmacokinetics
Cytochrome P-450 CYP3A
Tricyclic Antidepressive Agents
Hydroxylation
Area Under Curve
Half-Life

Keywords

  • CYP2D6
  • CYP3A4
  • desipramine
  • drug interaction
  • imipramine
  • ketoconazole

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. / Spina, E.; Avenoso, A.; Campo, G. M.; Scordo, M. G.; Caputi, A. P.; Perucca, E.

In: British Journal of Clinical Pharmacology, Vol. 43, No. 3, 1997, p. 315-318.

Research output: Contribution to journalArticle

Spina, E. ; Avenoso, A. ; Campo, G. M. ; Scordo, M. G. ; Caputi, A. P. ; Perucca, E. / Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. In: British Journal of Clinical Pharmacology. 1997 ; Vol. 43, No. 3. pp. 315-318.
@article{3a45af75ff9041789cac79d0aefab586,
title = "Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects",
abstract = "Aims: The aim of the study was to characterize further the role of CYP3A4 in the metabolism of tricyclic antidepressants. Methods: The effect of oral ketoconazole (200 mg day-1 for 14 days) on the kinetics of a single oral dose of imipramine (100 mg) and desipramine (100 mg) was evaluated in two groups of six healthy male subjects. Results: Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 ± 0.21 to 0.96 ± 0.20 l h-1 kg-1, mean ± s.d.; P <0.02), a prolongation in imipramine half-life (from 16.7 ± 3.3 to 19.2 ± 5.4 h, P <0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 ± 1707 to 3180 ± 1505 nmol l-1 h, P <0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected. In the subjects given desipramine, no significant changes in desipramine and 2-hydroxy-desipramine kinetics were observed during ketoconazole treatment. Conclusions: These findings indicate that ketoconazole, a relatively specific inhibitor of CYP3A4, inhibits the N-demethylation of imipramine without affecting the 2-hydroxylation of imipramine and desipramine. This interaction, confirms that CYP3A4 plays a role in the demethylation of tricyclic antidepressants.",
keywords = "CYP2D6, CYP3A4, desipramine, drug interaction, imipramine, ketoconazole",
author = "E. Spina and A. Avenoso and Campo, {G. M.} and Scordo, {M. G.} and Caputi, {A. P.} and E. Perucca",
year = "1997",
language = "English",
volume = "43",
pages = "315--318",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects

AU - Spina, E.

AU - Avenoso, A.

AU - Campo, G. M.

AU - Scordo, M. G.

AU - Caputi, A. P.

AU - Perucca, E.

PY - 1997

Y1 - 1997

N2 - Aims: The aim of the study was to characterize further the role of CYP3A4 in the metabolism of tricyclic antidepressants. Methods: The effect of oral ketoconazole (200 mg day-1 for 14 days) on the kinetics of a single oral dose of imipramine (100 mg) and desipramine (100 mg) was evaluated in two groups of six healthy male subjects. Results: Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 ± 0.21 to 0.96 ± 0.20 l h-1 kg-1, mean ± s.d.; P <0.02), a prolongation in imipramine half-life (from 16.7 ± 3.3 to 19.2 ± 5.4 h, P <0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 ± 1707 to 3180 ± 1505 nmol l-1 h, P <0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected. In the subjects given desipramine, no significant changes in desipramine and 2-hydroxy-desipramine kinetics were observed during ketoconazole treatment. Conclusions: These findings indicate that ketoconazole, a relatively specific inhibitor of CYP3A4, inhibits the N-demethylation of imipramine without affecting the 2-hydroxylation of imipramine and desipramine. This interaction, confirms that CYP3A4 plays a role in the demethylation of tricyclic antidepressants.

AB - Aims: The aim of the study was to characterize further the role of CYP3A4 in the metabolism of tricyclic antidepressants. Methods: The effect of oral ketoconazole (200 mg day-1 for 14 days) on the kinetics of a single oral dose of imipramine (100 mg) and desipramine (100 mg) was evaluated in two groups of six healthy male subjects. Results: Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 ± 0.21 to 0.96 ± 0.20 l h-1 kg-1, mean ± s.d.; P <0.02), a prolongation in imipramine half-life (from 16.7 ± 3.3 to 19.2 ± 5.4 h, P <0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 ± 1707 to 3180 ± 1505 nmol l-1 h, P <0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected. In the subjects given desipramine, no significant changes in desipramine and 2-hydroxy-desipramine kinetics were observed during ketoconazole treatment. Conclusions: These findings indicate that ketoconazole, a relatively specific inhibitor of CYP3A4, inhibits the N-demethylation of imipramine without affecting the 2-hydroxylation of imipramine and desipramine. This interaction, confirms that CYP3A4 plays a role in the demethylation of tricyclic antidepressants.

KW - CYP2D6

KW - CYP3A4

KW - desipramine

KW - drug interaction

KW - imipramine

KW - ketoconazole

UR - http://www.scopus.com/inward/record.url?scp=0031057666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031057666&partnerID=8YFLogxK

M3 - Article

C2 - 9088587

AN - SCOPUS:0031057666

VL - 43

SP - 315

EP - 318

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 3

ER -